Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil

HPB

Volumn 15, Issue 6, 2013, Pages 428-432

  Arshad, Ali ^a   Chung, Wen Y ^a   Steward, William ^b   Metcalfe, Matthew S ^a   Dennison, Ashley R ^a  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR; GEMCITABINE; GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; LIPIDEM; OMEGA 3 FATTY ACID; PLATELET DERIVED GROWTH FACTOR; UNCLASSIFIED DRUG; ANGIOGENIC PROTEIN; ANTINEOPLASTIC AGENT; AUTACOID; DEOXYCYTIDINE; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; TUMOR MARKER;

ADVANCED PANCREATIC CANCER; ARTICLE; DRUG MECHANISM; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOWN REGULATION; ENGLAND; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; STATISTICAL MODEL; TIME FACTOR;

ADMINISTRATION, INTRAVENOUS; ANGIOGENIC PROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CYTOKINES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ENGLAND; FATTY ACIDS, OMEGA-3; FIBROBLAST GROWTH FACTORS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; PANCREATIC NEOPLASMS; PLATELET-DERIVED GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877699814     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12002     Document Type: Article

References (22)

1. Arshad A, Al-Leswas D, Al-Taan O, Stephenson J, Metcalfe M, Steward WP, et al. (2011) Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer. Am J Clin Oncol. PMID:21436672 [Epub ahead of print 2011/03/23].
2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
3. Ugurel S, Rappl G, Tilgen W, Reinhold U,. (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19: 577-583. (Pubitemid 32112873)
4. Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, et al. (2010) Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer 10: 203.
5. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, et al. (2001) Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7: 1258-1262. (Pubitemid 32708678)
6. Rahbari NN, Reissfelder C, Muhlbayer M, Weidmann K, Kahlert C, Buchler MW, et al. (2011) Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann Surg Oncol 18: 2182-2191.
7. Poon RT, Fan ST, Wong J,. (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19: 1207-1225. (Pubitemid 32176299)
8. Poon RT-P, Lau CP-Y, Cheung ST, Yu WC, Fan ST,. (2003) Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 63: 3121-3126.
9. Philip PA, Benedetti J, Corless CL, Wong R,. (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610.
10. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB) 80303. J Clin Oncol 28: 3617-3622.
11. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966. (Pubitemid 46972777)
12. Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, et al. (2011) Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 11: 286.
13. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K,. (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88: 2239-2245. (Pubitemid 30247122)
14. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm W Jr, Richter A, et al. (2002) High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25: 122-129. (Pubitemid 34815907)
15. Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC, et al. (2008) Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 37: 145-150.
16. Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, et al. (2007) Platelet-derived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 67: 5201-5210. (Pubitemid 46997258)
17. Shen J, Vil MD, Zhang H, Tonra JR, Rong LL, Damoci C, et al. (2007) An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody. Biochem Biophys Res Commun 357: 1142-1147. (Pubitemid 46693690)
18. Katano M, Nakamura M, Fujimoto K, Miyazaki K, Morisaki T,. (1998) Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma. Ann Surg 227: 365-371. (Pubitemid 28131017)
19. Sulzbacher I, Birner P, Trieb K, Träxler M, Lang S, Chott A,. (2003) Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 16: 66-71. (Pubitemid 36152688)
20. Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, et al. (2009) The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur J Cancer 45: 2077-2086.
21. Arshad A, Al-Leswas D, Stephenson J, Metcalfe M, Dennison A,. (2011) Potential applications of fish oils rich in n-3 fatty acids in the palliative treatment of advanced pancreatic cancer. Br J Nutr 106: 795-800.
22. Baumann KH, Hessel F, Larass I, Müller T, Angerer P, Kiefl R, et al. (1999) Dietary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Arterioscler Thromb Vasc Biol 19: 59-66. (Pubitemid 29031913)